Skip to main content
TipRanks
Go Ultimate75% OFF

Acme United (ACU) AI Stock Analysis

186 Followers
ACU

Acme United

(NYSE MKT:ACU)

Select Model
Rating:72Outperform
Price Target:$78.00â–²(17.24% Upside)
Action:upgraded
Date:11/11/26

ACU scores well overall primarily due to strong technical momentum and a notably positive earnings call with constructive Q4/2027 outlook. Financials are steady but held back by softer recent free-cash-flow growth and higher debt versus recent periods. Valuation is a modest headwind given the ~23.8 P/E and ~0.91% dividend yield.

Positive Factors
Broad Revenue GrowthGrowth extends beyond the acquired My Medic business, indicating that Acme is generating organic demand across its established product portfolio. Broad-based expansion in First Aid, Westcott, and international markets can strengthen distribution relationships and provide a durable base for continued revenue gains.
Negative Factors
Higher Net DebtThe increase in net debt reduces financial flexibility after acquisitions, dividends, and product investments. Greater borrowing also raises exposure to interest expense and makes inventory or integration setbacks more consequential, potentially limiting the company's ability to pursue growth while maintaining balance-sheet resilience.

Acme United (ACU) vs. SPDR S&P 500 ETF (SPY)

-20%0%20%40%60%80%100%120%ACU+88.82%SPY+13.31%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$263.97M
Dividend Yield
0.96%
Average Volume (3M)
40.66K
Price to Earnings (P/E)
22.6
Beta (1Y)
0.31
Revenue Growth
13.13%
EPS Growth
11.31%
Country
US
Employees
649
Sector
Consumer Defensive
Sector Strength
62
Industry
Household & Personal Products

Acme United Business Overview & Revenue Model

Company Description

Acme United Corporation is a global supplier specializing in first aid, safety, cutting, sharpening, and measuring tools. Its products cater to a diverse clientele across educational institutions, households, corporate offices, hardware stores, sport...

How the Company Makes Money

Acme United makes money primarily by selling branded physical products to retailers, distributors, and other business customers. Revenue is generated from (1) the sale of first aid and safety products—such as first aid kits and related safety supplie...

Acme United Earnings Call Summary

Earnings Call Date:Oct 27, 2026(Q3-2026)|% Change Since:4.64%|Next Earnings Date:Mar 04, 2027
Earnings Call SentimentPositive

The call was strongly positive overall. Acme reported 18% quarterly sales growth, 80% net income growth, 74% earnings-per-share growth, improved gross margins, strong U.S. and international performance, positive My Medic contribution, expanding Spill Magic capacity, strong cash generation, and a favorable near-term outlook. The main challenges were higher SG&A, DMT closure costs, increased net debt and inventory, elevated freight and inflation, supply chain risks, and potential consumer pressure, but management described active measures to address these issues and continued growth opportunities for 2027.

Positive Updates

Strong Third-Quarter Sales Growth
Net sales were $58 million compared to $49.1 million in the third quarter of 2025, an increase of 18%. Excluding My Medic, sales increased 10%.

Negative Updates

Higher SG&A Expenses
Third-quarter SG&A expenses were $21.8 million, or 37.6% of sales, compared with $16.2 million, or 32% of sales, in the same period of 2025. First-nine-month SG&A was $60.7 million, or 35% of sales, compared with $47.5 million, or 32% of sales, in 2025. The increase was primarily due to the addition of My Medic, while the higher percentage of sales reflected increased advertising for the direct-to-consumer My Medic business and included $1 million of variable compensation related to the tariff refund.

Company Guidance

Management said the fourth quarter is expected to be seasonally strong in both sales and earnings and that it is projecting a solid fourth quarter of 2026; savings from closing the DMT plant are expected to be over $1 million annually, beginning in January 2027, and the latest SmartCompliance First Aid kit is planned to begin shipping in January 2027. The company has already booked new business for 2027, expects normal promotions next year if conditions remain unchanged, and said that, if consumer conditions stay the same, it is looking at a very good 2027 with the Westcott business as well as First Aid. Management also said it expects sometime in the next 12 months there'll probably be another deal, noting that every year it winds up doing at least one, and that it personally thinks the company will bring inventory into cash during 2027.

Acme United Financial Statement Overview

Summary

Steady TTM revenue growth (~4.2%) with stable profitability (TTM gross margin ~41.7%, net margin ~5.1%) supports a solid base. Offsetting this, cash flow is softer (TTM FCF growth down ~10.9% and operating cash flow coverage vs. obligations below 1.0), and leverage has risen versus recent years despite a still-manageable debt-to-equity (~0.38).

Income Statement

72Positive

Balance Sheet

64Positive

Cash Flow

58Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue220.55M196.54M194.49M191.50M193.96M182.09M
Gross Profit91.92M77.41M76.35M72.21M63.56M64.80M
EBITDA21.37M21.15M20.44M30.90M10.64M20.15M
Net Income11.35M10.19M10.02M17.79M3.03M13.66M
Balance Sheet
Total Assets207.86M171.00M162.17M149.24M164.38M144.44M
Cash, Cash Equivalents and Short-Term Investments7.94M3.60M6.40M4.80M6.10M4.84M
Total Debt46.49M28.26M32.84M25.51M63.42M47.48M
Total Liabilities82.99M53.39M55.19M51.34M85.35M67.36M
Stockholders Equity124.87M117.61M106.98M97.90M79.03M77.08M
Cash Flow
Free Cash Flow13.80M7.58M4.83M23.92M-1.71M-1.23M
Operating Cash Flow19.07M18.23M11.98M28.90M2.89M5.14M
Investing Cash Flow-21.50M-12.30M-12.94M7.43M-14.23M-6.37M
Financing Cash Flow5.26M-8.88M2.00M-38.44M14.28M2.04M

Acme United Technical Analysis

Technical Analysis SentimentNeutral
Last Price66.53

Price Trends

50DMA64.24Positive
100DMA59.66Positive
200DMA51.56Positive

Market Momentum

MACD1.52Positive
RSI49.35Neutral
STOCH33.42Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACU, the sentiment is Neutral. The current price of 66.53 is below the 20-day moving average (MA) of 67.37, above the 50-day MA of 64.24, and above the 200-day MA of 51.56, indicating a neutral trend. The MACD of 1.52 indicates Positive momentum. The RSI at 49.35 is Neutral, neither overbought nor oversold. The STOCH value of 33.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ACU.

Acme United Risk Analysis

Acme United disclosed 34 risk factors in its most recent earnings report. Acme United reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

2 New Risks
1.The use of artificial intelligence by us and third parties dealing with us presents operational and regulatory risks for our business.Q4, 2025
2.Changes in United States and foreign laws and policies governing international trade, export controls, manufacturing, and investment in the jurisdictions where we currently source or sell products, and any negative consequences resulting from such changes, could materially affect our business.Q4, 2024

Acme United Peers Comparison

Overall Rating

UnderperformOutperform
Sector (62)

Financial Indicators

ACU against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ACUACU72Outperform$263.97M22.599.45%0.96%13.13%11.31%
Sector *62Neutral$20.33B14.63-3.31%3.23%1.93%-12.26%
SLSNSLSN57Neutral$113.04M38.4818.04%―-1.95%122.62%
SKINSKIN54Neutral$98.46M-5.32-32.09%―-4.41%-51.42%
EPCEPC51Neutral$1.31B-24.92-3.53%2.11%-10.21%-310.40%
NUSNUS41Neutral$191.30M-0.81-34.83%6.11%-15.27%-318.35%

* Consumer Defensive Sector Average

Performance Comparison

-50%0%50%100%ACUNUSEPCSLSNSKINDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ACU and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ACUAcme United Corporation.66.5331.3589.09%
NUSNu Skin Enterprises3.93-5.27-57.27%
EPCEdgewell Personal Care Co28.3811.9873.08%
SLSNSolesence, Inc1.60-0.27-14.44%
SKINBeauty Health Company15.05-11.15-42.56%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 11, 2026